Journal Article A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR

ARATA, Suguru  ,  OHSHIMA, Shigetoshi  ,  GOTO, Takashi  ,  MIURA, Kouichi  ,  KOMATSU, Masafumi  ,  NAKANE, Kunio  ,  YAGISAWA, Hitoshi  ,  TAWARAYA, Hironobu  ,  NAKAJIMA, Kou  ,  FUNAOKA, Masato  ,  HOSHINO, Takao  ,  KURAMITSU, Tomoyuki  ,  FUJISHIMA, Yuukou  ,  WATANABE, Daisuke  ,  AJIMINE, Takuma  ,  OHNISHI, Hirohide

43 ( 1 )  , pp.29 - 37 , 2016-06-30 , 秋田医学会
ISSN:03866106
NCID:AN00009294
Description
AIM : To compare the efficacy and safety of triple therapy with simeprevir (SMV) against tripletherapy with telaprevir (TPV) while treating chronic hepatitis C (CHC).METHOD : A total of 230 CHC patients were enrolled in the present study. One hundredforty-three patients were treated with TPV, and 87 patients were treated with SMV. Univariateanalyses were performed to evaluate the pretreatment factors contributing to a sustained virologicalresponse at 24 weeks after the end of treatment (SVR24) and adverse events in the TPV andSMV groups.RESULT : The SVR24 rates in the TPV and SMV groups were 81.1% and 76.8%, respectively.The difference was not statistically significant. In the TPV group, the rates of anemia, nauseaand renal dysfunction were significantly higher than those in the SMV group.CONCLUSION : In the present study, the SVR24 rates achieved by the two therapies did notdiffer to a statistically significant extent. However, the rates of some adverse events in the TPVgroup were significantly higher than those in the SMV group. SMV was associated with low riskand a high SVR24 rate in patients with HCV.
Full-Text

http://air.lib.akita-u.ac.jp/dspace/bitstream/10295/3145/1/akitai43-1%2829%29.pdf

Number of accesses :  

Other information